Drugs / Gimsilumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04351243 | Apr → Dec 2020 | COVID-19 | Kinevant Sciences GmbH | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01357759 Comparator | May 2013 → Jul 2014 | rheumatoid arthritis | Morphotek | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gimsilumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04351243 ↗ |
| Known as | MORAb-022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01357759 ↗ |
| Modality | Monoclonal antibody | “Gimsilumab is a fully human monoclonal antibody (mAb).” NCT04351243 ↗ |
| Route | Intravenous | “IV infusion of MORAb-022” NCT01357759 ↗ |
| Target | CSF2 | “Gimsilumab is a monoclonal antibody against granulocyte macrophage-colony stimulating factor (GM-CSF)” NCT04351243 ↗ |